Endovia Health Sciences profit margin EDVA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- n/m
- a quarter missing
- Peer median
- −5.6%
Endovia Health Sciences' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | n/a |
| FY2024 | n/a | n/a | 8.6% |
| FY2023 | n/a | −81.1% | 29.5% |
| FY2022 | n/a | n/a | 32.7% |
| FY2021 | n/a | n/a | 22.8% |
| FY2020 | n/a | n/a | 18.8% |
| FY2019 | n/a | n/a | 19.5% |
| FY2018 | 5.2% | 5.1% | 53.8% |
| FY2017 | −16.5% | −17.6% | 50.8% |
| FY2016 | −2.6% | −2.7% | 53.3% |
| FY2015 | 2.1% | 2.1% | 52.4% |
| FY2014 | −9.6% | −9.2% | 55.9% |
| FY2013 | −6.5% | 0.1% | 50.3% |
| FY2012 | −4.1% | −3.0% | 57.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | n/a | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | −81.1% | |
| Q3 FY23 | −94.5% | n/a | −80.0% |
Against its peers
Companies in Beverages - Non-Alcoholic nearest Endovia Health Sciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| EDVAEndovia Health Sciences | n/m |
| IPSTIP Strategy | n/m |
| AMSSAmass Brands | n/m |
| YHCLQR House | n/m |
| REEDReed'S | −63.5% |
| WVVIWillamette Valley Vineyards | −5.9% |
| SRXHSRX Global | n/m |
| BUDABuda Juice | n/m |
| ZVIAZevia PBC | −5.3% |
| BRCCBRC | −0.9% |
| SUJASuja Life | n/m |
| Peer median | −5.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Endovia Health Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.